

VEOZA™ (fezolinetant) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause*¹

VEOZA™
fezolinetant

NONHORMONAL

TREAT TARGETED WITH NONHORMONAL VEOZA


VEOZA first-in-class NK3R antagonist that targets specific neurons in the hypothalamus, which are a source of VMS.^{2,3}

*See section 5.1 in SmPC

HOW VMS START IN THE HYPOTHALAMUS

Homeostasis


KNDy neurons in the hypothalamus are inhibited by oestrogen and stimulated by the neuropeptide NKB. The balance between inhibition and activation contributes to **body temperature regulation**³



Menopause

Oestrogen decline during the menopause transition and disrupts the balance between activation by NKB and inhibition by oestrogen.


Unopposed, NKB signalling causes heightened KNDy neuronal activity. This triggers heat dissipation mechanisms, including vasodilation and sweating – VMS³



HOW VEOZA DISRUPTS HOT FLUSHES

Blocking NKB to reduce heat

VEOZA selectively binds to the NK3 receptor to **block NKB** from binding on the KNDy neuron. This action is postulated to restore the balance in KNDy neuronal activity in the thermoregulatory centre of the hypothalamus²



OESTROGEN



OESTROGEN RECEPTOR ALPHA (ER α)



NKB



NK3 RECEPTOR

KNDy=kisspeptin/neurokinin B/dynorphin; NK3=neurokinin 3; NKB=neurokinin B; VMS=vasomotor symptoms; NK3R=neurokinin 3 receptor

Learn more at [VEOZA.se](https://www.veoza.se)

THIS MEDICINAL PRODUCT IS SUBJECT TO ADDITIONAL MONITORING

REDEFINE HOW YOU TREAT MENOPAUSAL VMS

VEOZA™ (fezolinetant) 45 mg film-coated tablets

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Pharmacotherapeutic group: Other gynaecologicals, ATC code: G02CX06. **Therapeutic indications:** VEOZA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see Section 5.1 in the Summary of Product Characteristics (SmPC)). ***Posology:** Recommended dose is 45 mg once daily. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients; concomitant use of moderate or strong CYP1A2 inhibitors; known or suspected pregnancy. ***Special warnings and precautions for use:** Diagnosis must include medical (including family) history. During treatment, periodic check-ups must be carried out according to standard clinical practice. **Liver function tests:** Must be performed prior to treatment initiation and monthly during the first three months; thereafter based on clinical judgement. Treatment should not be started or continued if test results meet pre-defined criteria. Patients should be informed about signs and symptoms of liver injury and advised to contact their doctor immediately if these occur. **Liver / renal disease:** VEOZA is not recommended for use in individuals with Child-Pugh Class B (moderate) or C (severe) chronic hepatic impairment, nor in individuals with

severe renal impairment. VEOZA is not recommended in women undergoing oncologic treatment for breast cancer or other oestrogen-dependent malignancies, nor in women using hormone replacement therapy with oestrogens (local vaginal preparations excluded). VEOZA has not been studied in women over 65 years of age, nor in women with a history of seizures or other convulsive disorders. Animal studies have shown reproductive toxicity. ***Undesirable effects:** The listed adverse drug reactions are insomnia, diarrhoea, abdominal pain, increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST), all with a frequency of less than 10%, and drug-induced liver injury with unknown frequency. **Marketing authorisation holder:** Astellas Pharma Europe B.V., The Netherlands.

Sweden: Status of the product: Rx. **Reimbursement:** (F) Subsidized only where menopausal hormone treatment is contraindicated or where menopausal hormone treatment has been discontinued for medical reasons. **Local representative:** Astellas Pharma AB, Tel: +46 (0)40 650 15 00. For more information, pack size and price see www.fass.se.

Based on authorised SmPC dated 07 February 2025.

***The section has been rewritten and/or abbreviated compared to the authorised SmPC. The SmPC can be ordered free of charge from the local representative.**

REFERENCES: 1. VEOZA SmPC §4.1 02.2025. 2. VEOZA SmPC §5.1 02.2025. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681-94.



Astellas Pharma AB | Box 21046 | 200 21 Malmö, Sweden | Phone +46 40 650 1500 | www.astellas.com/se


VEOZA™
fezolinetant